- Generative AI for T-cell receptor design
- Built specifically for drug discovery teams, not bolt-on AI
- Scales to organization-wide healthcare rollouts
Etcembly
Generative AI for T-cell receptor design
SF6.9
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Mine literature for research signalsImmunotherapy and TCR research teams
Mine literature for research signalsImmunotherapy and TCR research teams
Best for
Immunotherapy and TCR research teams
Pricing
Custom
SoftFinders Score
6.9 / 10
Overview
What is Etcembly?
Etcembly is an AI immunotherapy company using machine learning to design T-cell receptor therapeutics for research programs. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.
The clearest fit for Etcembly is immunotherapy and TCR research teams, and the product leans into generative AI for T-cell receptor design. One real limitation: early-stage pipeline and narrow focus. Pricing is sales-led and scoped per buyer rather than posted publicly. Confirm validation depth, support coverage, and the rollout plan before signing.
KEY FEATURES
What you get out of the box
Molecule Design
Generates and ranks small molecule candidates
Protein Modeling
Predicts and designs protein structures
Knowledge Graph
Connects biological and chemical knowledge sources
Virtual Screening
Screens compound libraries against targets
Literature Intelligence
Mines biomedical literature for relevant evidence
Multi Omics
Integrates genomic and other omics data sources
USE CASES
Where teams put it to work
Mine literature for research signals
Run virtual screens against targets
Collaborate with pharma partners
Bridge AI design and wet lab cycles
Identify drug targets from biology data
Accelerate molecule design cycles
Editorial Take
What we like, and what to verify
- Early-stage pipeline and narrow focus
- Drug success still depends on downstream trials
- Pricing is sales-led and needs scoping upfront
Screenshots
A look inside
Alternatives
Tools to consider next
Iktos SF 7.4
Why consider it
Generative chemistry and synthesis planning AI
Cradle SF 7.5
Why consider it
AI protein design for wet labs
Chai Discovery SF 7.3
Why consider it
Molecular structure prediction for discovery research
NOETIK SF 7.1
Why consider it
Spatial biology models for cancer targets
Generate Biomedicines SF 7.7
Why consider it
Generative protein design across modalities
Causaly SF 7.6
Why consider it
Biomedical evidence and reasoning for R&D
FAQ